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On Drugs 




Despite their centrality to medicine, drugs are not easily defined. We introduce two 
desiderata for a basic definition of medical drugs. It should: (i) capture everything 
considered to be a drug in medical contexts and (ii) rule out anything that is not 
considered to be a drug. After canvassing a range of options, we find that no single 
definition of drugs can satisfy both desiderata. We conclude with three responses to 
our exploration of the drug concept: maintain a monistic concept, or choose one of two 
pluralistic outcomes. Notably, the distinction between drugs and other substances is 
placed under pressure by the most plausible of the options available.   
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1. Introduction 
Medicine in both its current and historical forms is almost inconceivable without drugs. 
Virtually every aspect of medical care, from diagnosis to cure, involves the prescription 
and administration of drugs. But what exactly are drugs in the modern medical sense 
of the term? According to Benedetti, a pioneer of mechanism-based work on placebos, 
“defining a drug is an easy task”. A drug:  
 
…is a molecule delivered to the body to produce a biological effect. Its mode of 
action is to alter one or more biochemical pathways, for instance, by binding to 
a receptor or by modifying the activity of an enzyme (Benedetti 2014, 329). 
 
In contrast, our account shows that the task of defining medical drugs is far from easy. 
Not only is Benedetti’s definition too narrow, but there is no viable definition of what 
drugs are that includes all and only those substances that are considered to be drugs 
in modern medicine.  
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 Our paper is thus a first salvo against a conceptually monistic view of medical 
drugs: the idea that there is a single set of necessary and sufficient conditions that 
define the medical drug concept. Why target a monistic account of drugs? Why not 
simply assume a degree of conceptual pluralism from the outset? This would, after all, 
fit a growing trend within philosophy of science toward pluralism for a number of 
scientific concepts from a range of domains, including ‘concept’ itself (e.g., Dupré 
1999; Stotz, Griffiths and Knight 2004; Weiskopf 2009).  
One reason we begin with a monistic view is that conceptual monism seems to 
underlie much of the thinking about drugs within medicine and biomedical science. 
This is certainly evinced in Benedetti’s confident assertion above of what drugs are, 
but he is not alone. Most pharmacology textbooks begin with a brief but broad 
definition of drugs (see Section 3) and then quickly move on to the task of explaining 
how drugs work. 
 A second reason for focusing initially on a conceptually monistic view of drugs 
is that it could be true in the restricted medical context we investigate. If legal and 
recreational drug concepts were also part of our inquiry, then a pluralistic view of drugs 
might seem a reasonable starting point. Currently, however, there is no existing body 
of work in philosophy that strongly suggests a plurality of drug concepts operating 
within medicine. Indeed, there has been very little philosophical work on the nature of 
medical drugs, despite their central role in medical practice. A consideration of the 
drug concept needs to start somewhere, and investigating the case for conceptual 
monism is an efficient way to begin an overdue philosophical discussion of drugs.  
 Even if a singular account of drugs fails, which we ultimately show to be the 
case, there is value in starting our investigation from a monistic basis. An examination 
of this sort proceeds by offering an overarching definition of what drugs are, and then 
testing it against various criteria of adequacy. The fault-lines of various definitions tried 
in this manner are likely to reveal the contours of any underlying plurality of concepts. 
The failure of any single drug definition to do what is required of it tells us something 
about where distinct but related drug concepts may lie in relation to one another.  
In this paper, we canvass a range of options for defining drugs and show that 
none of them is adequate. We begin, in Section Two, by saying a bit more about the 
motivations behind our project before identifying two desiderata for an adequate 
definition of the drug concept. In Section Three, we look to pharmacology for guidance, 
and analyse existing pharmacological definitions to draw out a list of properties that 
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might be used as a basis for developing a definition of the drug concept. We also 
briefly consider natural kind-definitions before, in Section Four, pressing on to look at 
functional kind-definitions. Finally, in Section Five, we consider social kind-definitions. 
In all cases, we find no definition of drugs that satisfies the basic desiderata laid down 
in Section Two. We conclude, in Section Six, by presenting three responses to our 
exploration of the drug concept: one revisionary monistic conception, and two 
pluralistic accounts of drugs. We suggest that on the two most plausible options, a 
distinction between drugs and some putatively non-drug substances is difficult to 
sustain.  
 
2. Three Motivations and Two Desiderata 
 
Our conceptual analysis of drugs has three main motivations. First, drugs play a 
major role in treatment, which is probably the core and very rationale of medicine, and 
is thus important to any philosophy of medicine. While it is unlikely that treatment can 
be defined exclusively in terms of drugs, the administration of a drug for therapeutic 
purposes does appear to be at least a sufficient condition for medical treatment. A 
drug may also feature as part of a necessary condition on treatment. Medical 
treatments might simply consist of a certain set of therapies, one of which is drug 
therapy. This does not, of course, serve as anything like a deep account of treatment, 
and we are not offering a conceptual analysis of it. The point is merely that drug 
therapy is central to treatment in medicine, and so a clearer understanding of what 
drugs are is likely to help us better understand the philosophical nature of treatment. 
Drugs, via their connection to treatment, may also play a role in clarifying 
notions of health and normal functioning, which are probably the most debated issues 
in philosophy of medicine (e.g., Griffiths and Matthewson 2018; Ereshefsky 2009). 
Consider a diabetic who takes insulin. When a person’s body produces insulin of its 
own accord in the course of normal functioning, the chemical is not considered to be 
a drug. However, once the body stops producing insulin and that chemical is 
subsequently administered to the body, at that point insulin is a drug. One sign of 
abnormal functioning, then, is the need to replace a chemical produced by the body 
with a drug. Drugs are capable of restoring normal function in specific circumstances. 
A similar point can be made about health. One marker of ill-health is the chronic need 
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to take a drug. Taking a drug is thus potentially sufficient to identify both abnormal 
functioning and ill-health. 
A definition of what drugs are can also help us shed light on certain pressing 
demarcation questions. This is our second motivation. One demarcation question 
concerns the relationship between drugs and placebos. Much of the literature on 
placebos, both within medicine and within philosophy, sets placebos up in 
fundamental opposition to drugs (Miller and Brody 2011). One fairly natural line of 
thought is that the difference between drugs and placebos lies in their mode of action. 
While both placebos and drugs can bring about therapeutic benefits, the main causal 
action of a placebo is via our beliefs, whereas the main causal action of a drug is via 
some biochemical pathway. To put the point somewhat provocatively, as others have 
(e.g., Colloca and Benedetti 2005), placebos alter the mind, whereas drugs alter the 
body. 
Whether this distinction holds up to scrutiny depends on how drugs and 
placebos work. It has long been acknowledged how difficult it is to define the concept 
of a placebo and in particular, to identify placebo effects (Kienle and Kiene 1997; Miller 
and Brody 2011). However, because placebos are set up in opposition to drugs, it may 
be the case that the conceptual difficulties surrounding the notion of a placebo are 
partly due to a corresponding lack of clarity surrounding drugs. Thinking about drugs 
might help us not only to answer the question of whether placebos are drugs, but also 
to understand what placebos are. Matters are complicated by the fact that many 
placebo chemicals (e.g., lactose, fatty acids) can produce physiological effects of the 
kind that are normally associated with drugs (Golumb et al. 2010). If the relevant 
chemical that is being administered as a placebo has the potential for a positive health 
outcome, and that outcome can be linked to the chemical action of the placebo, then 
the gap between placebos and drugs would seem to be narrowed (Benedetti 2014).  
Aside from posing a conceptual conundrum, the contrast between placebos 
and drugs influences how we think about the use of placebos as a control substance 
in clinical trials. Trials to establish the efficacy of a specific drug are often measured 
against the efficacy of a placebo. Clinicians often see such comparisons as a way of 
comparing the drug to an ‘inert’ or ‘non-active’ substance (Miller and Brody 2011). 
There is a question, then, about whether placebos are an appropriate control 
substance. If they are drugs, and this has not been properly recognised, then the 
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failure to view placebos as potential drugs, with chemical pathways of their own, may 
lead to misinterpretations of clinical trial results.  
There is also the question of why placebos with demonstrated efficacy are not 
generally recommended as drug-based therapies alongside whatever drug they were 
tested against in clinical trials. Anti-depressants are a case in point. In a now-famous 
meta-analysis, Kirsch et al. (2002) argued that more than 80% of the effect of 
antidepressants is a placebo effect. The authors concluded that anti-depressants are 
not, in fact, very effective. An alternative conclusion is that there are two categories of 
anti-depressant drug, one of which is more effective than the other (i.e., the placebo 
‘drug’), but that line of thought is not taken very seriously. Drugs clearly occupy a 
position in medical treatment that placebos do not. A conceptual analysis of drugs can 
help us to understand this perceived difference between placebos and drugs and even 
challenge it (if, for instance, a conceptual distinction between drugs and placebos is 
ultimately unsustainable). 
Another demarcation challenge arises for excipients. Excipients are constituents 
of medicines that aid in the delivery of a particular chemical to a physiological system 
(e.g., the material in an aspirin tablet, apart from the acetylsalicylic acid, that helps in 
the drug's stability, gastric disintegration and systemic absorption). As with placebos, 
there is a tendency to draw a distinction between excipients and drugs. The excipient 
is the 'inert' or 'inactive' component of a medicine, whereas the drug is the 'active' 
component of the medicine (Jivraj, Martini and Thomson 2000).   
There is, however, an increasing awareness that excipients are not as 'inert' as 
previously thought. Excipients can and do interact with the rest of the chemical 
constituents of a medication to produce unwanted or unexpected effects (Pifferi and 
Restani 2003; Haywood and Glass 2011). Moreover, excipients can sometimes be 
used for therapeutic purposes in other contexts. For instance, stearic acid is a 
commonly used excipient because of its low toxicity. However, it has also been used 
therapeutically as a topical cream for burns in mice (Khalil et al. 2000). This raises a 
similar question to the one in the placebo case, namely: are excipients drugs? If the 
answer is ‘yes’, then this has clear implications for how to view the supposedly inert 
substances that are coupled with drugs for the purposes of administration. If the 
answer is ‘no’, then it would be useful to know exactly why. 
Finally, determining what drugs are would help to distinguish pharmacology from 
other sciences. Pharmacology is supposed to be the distinctive science of drugs. 
 6 
However, without an account of what drugs are, it is difficult to differentiate 
pharmacology from the broader study of chemical interactions within biological 
organisms (biochemistry) or even from the study of chemicals (chemistry). Such a 
distinction would also shed light on certain normative questions: why should we 
apportion funding and resources to pharmacology per se over biochemistry or 
chemistry more broadly? 
To frame our investigation into all these questions, we suggest two desiderata for 
an adequate definition of the drug concept. Although there may be other criteria that 
could be included, satisfying these two desiderata is a condition on the minimal 
adequacy of a definition. We thus offer these desiderata not as a comprehensive guide 
to what the drug concept should be, but rather as a starting point for investigating that 
concept from an initially monistic outlook.  
First, a definition of medical drugs should capture everything that is considered to 
be a drug in medical contexts. It should not be the case, for example, that under a 
candidate definition paracetamol is in whereas antacids are out. If substances 
commonly taken to be medical drugs are excluded by any supposedly unifying 
definition, the consequences of that exclusion should be justifiable and acceptable to 
pharmacological and medical practice. Likewise, if the definition brings in substances 
that are normally excluded, their inclusion should be similarly justifiable and 
acceptable.  
How do we determine whether a definition of drugs covers the relevant 
substances? This can be done by consulting a comprehensive drug compendium, 
which lists substances that are used medically. A prominent example is the drug bank 
compiled by the government-funded Canadian Institutes for Health Research.4 This 
list contains over thirteen thousand drug entries, which are searchable by molecular 
structure, therapeutic use, and countries where the drug is approved or actively used 
for medical purposes.5 Ideally, an overarching drug concept would be applicable to 
everything on this list.  
 
4 DrugBank Database, https://www.drugbank.ca/ (accessed 11 June 2020). For a recent overview of 
the database, see Wishart et al. (2018). 
5 There are other lists that we could have used. In the USA, the Drug Enforcement Agency (DEA) 
administers a list of controlled substances, and a similar list is maintained in the UK. Both lists, however, 
are focused on substances that are abused (rather than medically administered). Indeed, the DEA’s list 
categories drugs in terms of their likelihood to be abused (rather than their medical implementation). In 
Australia, the Therapeutic Goods Administration (TGA) maintains a list that is much closer to the 
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Second, a definition of what medical drugs are should capture only those things 
that are considered to be drugs in medical contexts. They should thus not include 
anything that is not considered to be a drug. In so far as there is any consensus on 
how to define drugs, it appears to be that food and nutrients are always deemed not 
to be drugs (Ritter et al. 2020). An adequate definition of what drugs are should thus 
not allow food or nutrients to qualify. Relatedly, it should not follow from a drug concept 
that eating food is a way of taking drugs, except when drugs are added to food. Ideally, 
criteria for dealing with food will illuminate other supposed non-drug substances 
currently categorized as placebos and excipients. 
  
3.  Pharmacological Definitions 
 
A basic definition of medical drugs should thus include all the substances taken to be 
medical drugs, and exclude all the substances that are not. An obvious place to begin 
our search for an overarching definition of the drug concept is pharmacology. We 
might even hope for some sort of pharmacological law that underpins the designation 
of every substance that counts as a drug. Unfortunately, when we look to 
pharmacology textbooks, we find very little agreement over what drugs are, even 
though pharmacologists recognise the importance of giving a clear and encompassing 
definition. From an analysis of pharmacological textbooks, we collated 24 explicit 
definitions of the drug concept.6 From these definitions, we can identify 10 
components that are used to define drugs, either in combination with one another or 
on their own: 
 
(1) Drugs are chemicals. 
(2) Drugs affect biological or physiological function. 
(3) Drugs have a specific manner of effect (i.e., through chemical action, by interaction 
with specific molecular components, thus modifying the response of a cell or tissue to 
its environment). 
(4) Drugs are used for the diagnosis or treatment of disease. 
(5) Drugs are administered. 
 
Canadian drug bank list in its scope. The TGA list does not, however, include many experimental drugs, 
which are part of the Canadian drug bank taxonomy. 
6 These definitions are available from the authors as a supplementary file.  
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(6) Drugs extend life. 
(7) Drugs alleviate pain or suffering. 
(8) A drug is a constituent of a medicine. 
(9) A drug is not a food or nutrient. 
(10) A drug is or could be listed in a pharmacopeia. 
 
A quick glance at these components reveals two things. First, definitions of drugs are 
surprisingly varied. Current definitions range from the exceedingly general definition 
of a drug as “a chemical that affects living tissues” (Bryant, Knights and Salerno 2011, 
2-3) to the more specific definition of drugs in terms of “molecules that interact with 
specific molecular components of an organism to cause biochemical and physiologic 
changes within that organism” (Alenghat and Golan 2017, 2). There is also a 
detectable cleavage in existing definitions between whether emphasis is placed on the 
biochemical or on the social features of drugs. Compare the above two definitions with 
the definition below that emphasises therapeutic use: 
 
Any substance or combination of substances presented as having properties 
for treating or preventing disease in human beings; Any substance or 
combination of substances which may be used in, or administered to, human 
beings, either with a view to restoring, correcting or modifying physiological 
functions by exerting a pharmacological, immunological or metabolic action, or 
to making a medical diagnosis (Article 1 of Directive 2001/83/EC (amended)).7 
  
Another notable feature of existing drug definitions is the tendency to try and rule out 
food by fiat. This not only speaks to the importance of identifying a concept that 
achieves the desired contrast with food, but also to the difficulty with which this 
contrast may be achieved in a principled way. For example:  
 
A drug can be defined as a chemical substance of known structure, other than 
a nutrient or an essential dietary ingredient, which, when administered to a 
 
7 EU definition of ‘medicinal products’, cited in the UK’s Medicines and Healthcare Products Regulatory 
Agency “A guide to what is a medicinal product”, March 2020, MHRA Guidance Note 8. 
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living organism, produces a biological effect. (our emphasis, Ritter et al. (2020) 
Chapter 1). 
 
Although pharmacology fails to provide a single cohesive definition of what drugs are, 
it does provide a great deal of source material on which a viable definition might be 
based. We can thus use the ten components identified above to examine how a 
definition of the drug concept might work.  
 A standard first move in the conceptual analysis of scientific concepts is to 
appeal to natural kinds. A traditional natural kind definition is one according to which 
there is some intrinsic physical property or cluster of intrinsic properties that are 
features of all drugs. Natural kind definitions are worth briefly considering because 
definitions along these lines do appear to underwrite some thinking about drugs. They 
are, for example, found in some pharmacology textbooks. In general, however, 
definitions of this kind in the case of drugs tend to be either far too broad or far too 
narrow. 
For instance, we could take the first component on the pharmacological list and 
just define drugs as chemicals. However, while it is plausibly a necessary condition on 
being a drug that it is a chemical, it can hardly be considered sufficient. There are 
clearly many chemicals that are not drugs (e.g., graphite, cobalt nitrate). Or, to take 
another example, suppose we say that all drugs are chemicals that share a certain 
structure. There is a range of molecular structures that drugs can have. These include 
inorganic salts (such as potassium chloride), small to moderate organic compounds 
(such as aspirin and other salicylates), and large complex proteins (such as insulin 
glargine). The trouble is that there is no common molecular structure that all drugs 
have in common even though there are classes of drugs that share a particular 
molecular structure.8 Determining such structure helps with drug classification, but not 
for defining what drugs, in general, are.  
There is one natural kind-style definition that we are particularly keen to set 
aside. We mention it only because it seems to be a popular way to think about medical 
drugs outside the medical community. This definition appeals to a distinction between 
drugs and ‘natural’ substances. It claims that the common property of all drugs is that 
 
8 For example, penicillin antibiotics are a family of antibiotics with a core structure of a B-lactam ring 
joined to a thiazolidine ring; however, unique R side chains differentiate different penicillin members 
by contributing to different pharmacological and chemical properties. 
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they are manufactured or artificially produced chemicals and so are unnatural. Non-
drugs—like food and nutrients—by contrast are natural substances, containing only 
chemicals that arise in nature. This definition fails, however, because the distinction 
between drugs and natural substances is open to numerous straightforward 
counterexamples. Acetylsalicylic acid (aspirin), for instance, can be derived from 
willow bark, and many other substances now considered drugs have similarly ‘natural’ 
origins. Indeed, according to Bade, Chan and Reynisson (2010), around 10% of drugs 
on the market are unaltered natural substances. 
 A much more plausible account of drugs focuses not on any intrinsic nature but, 
instead, on their functional biological properties: the specific manner in which they 
interact with biological organisms. In the next section, we will consider functional kind-
based accounts of drugs that do precisely this. 
 
4. Functional Kind Definitions 
 
Using the functions of drugs to define them means we need to focus not on 
what drugs are, intrinsically, but on what they do. In pharmacology, receptor theory 
has been the primary candidate for defining drugs in terms of their functional role. 
Historical discussion in the field reveals a quest for an underlying biological principle 
that not only distinguishes drugs from other chemicals but also explains and predicts 
how they work therapeutically in human bodies (e.g., Kenakin 2004; Parascandola 
and Jasensky 1974). Indeed, according to Rang (2006, S9), “Receptors lie … at the 
heart of pharmacology … they provide the basic framework and are [its] ‘Big Idea’”. 
As receptors transformed during the twentieth century from unknown 
theoretical entities into specific biological molecules (historically proteins), their role in 
drug action seemed to illuminate the nature of drugs. The basic idea is that there are 
certain proteins inside physiological systems that are either activated to bring about a 
certain effect when chemicals bind to regions on proteins, or are blocked from bringing 
about an effect via the same process of binding. These receptor proteins are 
separated into four distinct classes of drug ‘targets’, which have binding sites that 
drugs act upon: G-protein-coupled receptors, ion channels, enzymes, and transporter 
proteins (Ritter et al. 2020).  
One option for defining drugs in terms of their functional role, then, is to define 
drugs in terms of receptor binding with respect to these four molecular targets. 
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Definition 1 (D1): Drugs are chemicals that bind to one of four receptor 
molecules found within biological organisms. 
 
But this definition has many exceptions: there are drugs that operate without binding 
to one of these four receptors (e.g., carboplatin, which interferes with DNA in cancer 
cells to inhibit growth; or bisphosphonates used in the treatment of osteoporosis). 
These exceptions might indicate that we should try expanding the definition of 
what receptor molecules are. One broadened definition of a receptor is a ‘recognition 
molecule for a chemical mediator through which a response is transduced’ (Ritter et 
al. 2020, Chapter 2). The identification of several classes of receptor proteins thus 
offers a way to narrow the definition of drugs. Only certain chemicals bind to certain 
receptors. Not all chemicals are capable of binding to all or even some receptors in 
the relevant sense. A drug, from this perspective, is a chemical that binds to a 
particular receptor inside a physiological system (e.g., Neubig et al. 2003; Maehle 
2009).  
 
Definition 2 (D2): Drugs are chemicals that bind to receptor proteins inside 
biological organisms. 
 
D2 has the virtue of retaining receptor theory at the heart of the drug concept and thus 
capturing a widely held view about drugs in pharmacology, in which receptors are “the 
seminal concept that all classes of therapeutic agents produce their effects by acting 
as ‘magic bullets’ at discrete molecular targets [receptors]” (Winquist, Mullane and 
Williams 2014, 7). 
Unfortunately, D2 is too narrow. There are drugs that function without binding 
to anything, either protein or non-protein. Concentrated electrolytes, such as 
potassium salts, are an example. They work by creating, restoring or minimising a 
charge gradient across a cell membrane. Osmotic laxatives work in a similar way. 
Antacids are also considered drugs but they alter the pH of the stomach via chemical 
reaction rather than by binding to anything.  
Conversely, many processes in cells operate via binding mechanisms and yet the 
chemicals involved are not considered drugs. For instance, ATP, the energy 
conversion molecule in cells, binds to a variety of proteins in the everyday course of 
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cellular activity and organismal function. Antibodies bind to receptors on foreign 
entities but are not drugs, at least not when they occur endogenously. Likewise, 
enzymes—the workhorses of the cell—bind to all kinds of chemical substrates in the 
process of carrying out a huge range of basic cellular processes. But despite the 
centrality of binding to their activity, these endogenously produced molecules are not 
drugs. As Rang puts the point: 
 
Is there anything about drug‐receptor interactions that distinguishes them, as a 
class, from other kinds of biochemical goings‐on, that might justify the use of the 
specific term “receptor theory”? Not obviously (Rang 2006, S14). 
 
We could try expanding the definition of a drug even further, away from receptor 
theory and protein binding. We could focus only on the causal action of the drug in the 
most general terms. A drug is thus a chemical that induces a physiological change 
inside an organism (D3).  
 
Definition 3 (D3): Drugs are chemicals that induce physiological changes inside 
organisms. 
 
While D3 (or something like it) is a common enough definition to be found in 
pharmacology textbooks, it is far too broad. It easily includes essential nutrients, all of 
which have physiological effects on organisms. Food is a way of introducing 
chemicals—namely, nutrients—into an organism to bring about a physiological 
change.  
Can we find a ‘sweet spot’ between the too narrow definition of a drug as one 
that binds to receptors, and the too broad definition of a drug as something that 
induces a physiological change inside an organism? Put another way, can we give a 
functional kind-definition of what drugs are that achieves the desired contrast between 
drugs, on the one hand, and food and nutrients, on the other? One option might be to 
try and rule food out via an appeal to medicines, and in particular to the notion of drugs 
as the active component of medicines (D4). 
 
Definition 4 (D4): Drugs are the active ingredients of medicines.  
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 There are two problems with D4, however. First, it presumes some prior notion 
of a medicine that cleaves it apart from food. The notion of a medicine is no less in 
need of conceptual clarification than the notion of a drug itself. Second, at least some 
chemicals considered to be drugs do not straightforwardly contain an active ingredient. 
Consider, for instance, pro-drugs. Pro-drugs are substances that are introduced into 
the body but which have to be metabolized into another substance to carry out their 
designated activity (Rautio et al. 2008). It is the chemical outcome of the metabolic 
process that has the sought-after affect. Pro-drugs, according to the active ingredient 
view, cannot count as drugs because they do not contain the active ingredient, even 
though they ultimately help generate it. Of course, this depends on what ‘active 
ingredient’ means. But that is precisely our point: it’s not entirely clear how to specify 
the ‘active’ part of ‘active ingredient’ in such a manner that does not exclude various 
pro-drugs.  
Another difficulty with D4 is that it is far from obvious that the drug is always the 
active ingredient rather than the entire medicine. Consider medical uses of cannabis. 
Cannabis contains at least 400 different chemical compounds, of which 61 are 
considered to be cannabinoids (PubChem9). Of these 61, the two most well-known 
are Tetrahydrocannabinol (THC) and Cannabidiol (CBD). But many of the other 
cannabinoids are thought to modify the physiological effects of cannabis. It is not clear 
that there is a single active ingredient in cannabis, so much as a range of different 
chemicals having a systemic effect on an organism. Classifying drugs in terms of their 
active ingredients alone would cause considerable problems for cannabis and other 
such substances. 
 Another way to try and achieve the desired contrast between drugs and 
nutrients might be to try and define drugs in terms of a very specific type of causal 
pathway. Thus, one might accept that drugs and nutrients do the same thing in some 
cases, but the way in which drugs achieve their outcome is distinctive. Since we 
cannot use receptor theory to get the desired contrast, we would need some other way 
to differentiate the type of causal action. But hypothetically, at least, we could say: 
 
 
9 National Center for Biotechnology Information. PubChem Database. Cannabinoids, CID=9852188, 
https://pubchem.ncbi.nlm.nih.gov/compound/Cannabinoids (accessed on June 10, 2020). 
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Definition 5 (D5): A drug is a chemical with a specific type of causal action inside 
physiological systems. 
 
Aside from leaving the causal action of drugs dangerously underspecified, D5 faces a 
potential counterexample in the form of pro-drugs. As already noted, the type of causal 
pathway that leads from a pro-drug toward its effect is very similar, and plausibly of 
the same type, as the causal pathway that leads from some foods to nutrition.  
Indeed, for at least some pro-drugs the particular metabolic process that it 
undergoes mirrors the catabolic process involving glucose that produces ATP. A 
central aspect of the production of ATP involves the phosphorylation of glucose, in 
which a phosphoryl group is added to the glucose molecule. Some pro-drugs achieve 
their effects via a similar process. A drug used to treat COVID-19, remdesivir, is 
actually a pro-drug that, when administered, gets transformed by the addition of new 
molecular components within the cell via phosphorylation. The resulting chemical 
compound, which is considered the ‘active metabolite’, then interacts with a molecular 
target in order to achieve the desired effect. While remdesivir does not produce ATP, 
it is difficult to discern a difference in the causal mechanism that transforms remdesivir 
and the causal mechanism that transforms glucose.  
Perhaps another option for achieving the desired contrast between nutrients 
and drugs in terms of causal action would be to emphasize their different effects. For 
instance, we might base a definition of what drugs are on a prior distinction between 
sustaining life and improving health. Thus, a nutrient is a chemical that is needed to 
sustain the physiological processes that enable an organism to live, whereas a drug 
is a chemical that induces a physiological change that improves the health of an 
organism (but the organism does not require the chemical to live). 
 
Definition 6 (D6): Drugs are chemicals inducing physiological changes inside 
organisms that improve the organism’s health rather than merely sustaining the 
organism’s life. 
 
But the problem with D6 is that drugs such as insulin are used to sustain life. This 
means that the contrast between sustaining life and improving health fails to 
differentiate drugs from nutrients in terms of their causal outcomes.  
 15 
Perhaps, instead, we can understand drug outcomes with respect to a baseline 
of normal functioning (D6).  
 
Definition 6 (D6): A drug is a chemical that restores or improves normal 
functioning. 
 
The concept of ‘normal functioning’ is a contested notion, but whichever account is 
used, problems arise. Arguably, the contraceptive pill (a drug), when used to prevent 
pregnancy, prevents ‘normal function’ of the reproductive system. There are two ways 
of understanding normal function: statistical normality, and evolved normal function in 
which certain traits are normal because they are selected effects (Griffiths and 
Matthewson 2017). For the first, an assessment is made of what is typical of the 
reference class (let’s say, healthy women between 20 and 40 years old in Western 
societies). The large majority of these women can conceive and in the ‘normal’ course 
of affairs would do so. Contraception ends up creating a new normality (not 
conceiving). Only in the sense of this new statistical fact (that 50% or more of the 
population are taking contraceptives) are contraceptive drugs ‘restoring (new) normal 
function’. But this appears vacuous.  
The evolutionary case for normal function depends on populations and their 
reproductive capacities. Humans and other organisms succeed evolutionarily when 
they leave more offspring. Evolution can thus be thought of as ‘rewarding’ 
reproduction, which is a selected normal function. Contraception is in fact preventing 
the basic ‘normal’ thing humans have evolved to do: reproduce. Now of course 
contraception may enable better parental care of fewer offspring, and thus more 
evolutionary success, but it is not entirely clear that a standard evolutionary 
explanation can encompass the direct mechanism by which this is achieved 
(contraceptive drugs).  
The normativity of ‘normal’ might be what is preventing D6 from working. What 
if drug function could be tied to a law, and normativity thus left out of the picture? 
Pharmacology, it could be argued, supplies a range of pharmacological laws that 
specify how drugs function within biological systems. A definition could thus be 
provided in terms of these laws. One difficulty with this move is that the subject matter 
of pharmacology would have to be specified in order to delimit its laws. However, this 
specification requires first providing an account of what drugs are. One way to 
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overcome this problem would be to adopt an account of drugs that accepts a 
dependency between drug concepts and laws. A definition along these lines can be 
stated as follows:10 
 
Definition 7 (D7): X is a drug iff X features in a pharmacological law, where Y is 
a pharmacological law iff it relates drug concepts. 
 
 The basic idea is to define drugs and pharmacological laws mutually, rather 
than using one as a foundation for the other. The definition is circular, but not 
necessarily in an objectionable sense. Indeed, circularity of this kind may offer a way 
to bootstrap the analysis into better conceptual territory. It also allows for future 
updates in that new drugs might invoke existing laws or in some cases, help establish 
new laws, and vice-versa. 
One way of applying D7 is to start with a clear case of a drug. Any laws that 
apply to the drug immediately qualify as pharmacological laws in virtue of featuring 
drugs. We can then work back down from the laws and see what else the laws cover. 
Anything further that the laws cover is then also classed as a drug. The second way 
of applying D7 is to start with a clear case of a pharmacological law. Substances that 
are covered by the law immediately count as drugs. Ideally, through this back and 
forth, the analysis ends up with a set of substances that contains all and only those 
things considered to be drugs, along with a group of laws that operate on just those 
substances.  
 D7, if made to work, would certainly be a principled way in which to provide a 
functional analysis of drugs. Unfortunately, it seems to yield the wrong results. 
Suppose we start with the laws. The best candidates for pharmacological laws are the 
general principles that govern receptor theory. Such laws include the Hill-Langmuir 
equations and the Michaelis-Menten equation. Together, these equations form a 
quantitative model of receptor theory by describing the way in which enzymes bind to 
molecules over time (in the presence or absence of agonists and antagonists that can 
reverse the binding process) and how substances change in the presence of enzyme 
binding (Chou 1976; Colquhoun 2006). The problem is that these equations describe 
substances that are not drugs, and processes that are not generally associated with 
 
10 We are grateful to an anonymous referee for suggesting a definition along these lines. 
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drug effects. The Hill-Langmuir equations, for instance, also apply to food and 
nutrients that are metabolised by enzymes in the gut, via a metabolic process that 
binds nutrient molecules to enzyme receptors.  
Even if it were possible to specify or otherwise restrict the laws so that they do 
not apply to food and nutrients, there is also the issue of a great many drugs falling 
outside the scope of receptor theory. This problem could potentially be addressed by 
applying D7 in the second manner described above: by using drugs to specify the 
pharmacological laws. Thus, we start from those drugs that fall outside of receptor 
theory and work upward to additional pharmacological laws that operate on these 
substances. The trouble, however, is that there are drugs that when treated in this way 
will yield laws that encompass substances that are not drugs.  
One example is mitotic inhibitors, which are a specific class of cancer drugs. 
Mitotic inhibitors work by inhibiting cell-division. Such substances are therapeutic 
because they target the fast-growing cells that give rise to cancerous masses. A 
general law could be devised that describes the way these substances inhibit cell 
growth. The trouble, however, is that there are many substances that will also satisfy 
the law and which are not considered drugs. As Matson and Stukenberg (2011, 143) 
note, “it is clear that many compounds that result in mitotic arrest are neither useful 
therapeutics nor even effective at killing cells.” For instance, benomyl, a carbamate, 
inhibits mitosis in mammalian cells (Gupta et al. 2004) but it is not a drug; it is a 
fungicide commonly used in agriculture. In general, chemotherapy drugs are difficult 
cases because they blur the line between being toxic enough to treat cancer and not 
so toxic that they ultimately lead to death. There will be many cases in which two very 
similar substances, with similar functions, lie on different sides of that divide.  
In a general sense, then, the problem with functional definitions of drugs is that 
they are either too narrow, capturing at best receptor-based reactions, or they are too 
broad, capturing various kinds of metabolic processes or toxifying activities. It is 
difficult to strike the right balance between these competing demands in a principled 
way. Although we cannot rule out the possibility of defining drugs functionally via other 
means, it does not seem likely that focusing on their causal properties sets drugs apart 
from other kinds of chemicals (and nutrients in particular). Drugs do not seem, 
therefore, to be good candidates for a plausible account of functional kinds. 
 
6. Social Kind Definitions 
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So far, we have argued that neither natural kind nor functional kind definitions yield a 
satisfying account of what drugs are. This brings us to another way of defining drugs. 
Within the ten components of drug definitions that we identified in Section Three, there 
were distinctive social aspects. This suggests that being a drug is not a matter just of 
being a certain chemical, or of having a certain functional role but, rather, of being 
used for a particular socially defined purpose. In particular, drugs are administered by 
healthcare professionals for therapeutic ends (D8).    
 
Definition 8 (D8): A drug is a chemical that is administered within a medical 
context with the aim of bringing about a positive health outcome. 
 
D8 faces a familiar problem in that food is often prescribed in treatment contexts 
in order to improve health (e.g., the FOD-MAP diet for irritable bowel disease; low 
potassium diets for kidney disease). A particularly difficult case is total parenteral 
nutrition (TPN).11 TPN is a chemical infusion containing fat, glucose, amino acids, 
electrolytes, trace elements, vitamins and minerals. It is given to people who are 
unable to absorb nutrients in the ordinary way, through their stomachs. It is usually 
administered continuously over 12 to 24 hours, and can be administered as a short 
course for several days or on a long-term basis. The goal of administering TPN is 
clearly to bring about a positive health outcome. However, TPN contains the same 
nutrients as food (it is just that these nutrients are administered in a way that bypasses 
the stomach).  
The prospects for refining D8 to handle TPN are not good. The definition has 
two aspects: the notion of administration and the notion of a positive health outcome. 
TPN is administered in the same manner as a range of intravenous drugs, and so 
there is no way to draw a distinction between TPN and other substances via 
administration alone. The notion of a positive health outcome is similarly difficult to 
refine. The health outcomes related to TPN are analogous to the desired outcomes 
for many drugs. 
 
11 We thank an anonymous referee for suggesting TPN.   
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 In light of the difficulty facing D8, one option might be to shift the emphasis from 
medical treatment to a different kind of social criterion, namely: regulatory regimes 
(D9).  
 
Definition 9 (D9): A drug is a chemical that is subject to a specific set of 
healthcare regulations. 
 
According to D9, a drug is any chemical that is regulated inside a medical context, 
such as a hospital, surgery, pharmacy or medical practice in a specific way. What way 
is that? Presumably, whatever regulatory framework is imposed upon drugs in 
particular as opposed to other aspects of medical care.  
 The problem with D9 is that there is no single set of healthcare regulations that 
might be used to give substance to that specification, especially when we consider 
relevant international regulations. The controversial treatment of acidified sodium 
chlorite, for example, is not recognized as a drug in the USA, but counts as an ‘orphan 
drug’ in the EU for a motor neuron disease (EU/3/13/113912), even if evidence of its 
benefits are extremely limited.  
There is also a deeper problem with regulatory definitions of what drugs are. If 
we simply define drugs as any chemicals that fall under a certain set of medical 
regulations, it becomes unclear how we determine what these regulations should 
apply to in the first place. One option might be just to include a list of chemicals within 
the relevant regulatory framework. But then there is a question of how we decide what 
to include on the list and what to exclude from the list. Again, it is not possible to call 
on a prior conception of what drugs are to decide what the list should contain, because 
a drug is just anything that is on the list.  
A possible way forward might be to define drugs in normative terms. A drug 
would then be any chemical that should be regulated in a certain kind of way within 
healthcare contexts, rather than any chemical that is as a matter of fact on a list of 
regulated substances. Drugs could be defined as substances that should be regulated 
so as to minimise harm (D10). 
 
 
12 See the European Medicines Agency’s Press Release on 19 June 2013, available on their website 
(https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3131139, accessed 16 June 
2020). 
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Definition 10: A drug is a chemical such that its administration in a healthcare 
context ought to be regulated in order to minimise health-related harms. 
 
D10 faces at least two challenges. First, it is unclear what ‘health’ actually 
means. This is a much-contested notion in the philosophy of medicine (e.g., 
Ereshefsky 2009), and so invoking a notion of health-related harm to define drugs may 
turn out to be more difficult than defining drugs. For instance, does health-related harm 
include harms to mental health? Presumably it should in order to include psychiatric 
drugs, but then we need not only an account of physical health, but of mental health. 
Any definition of mental health would need to be at least consistent with a definition of 
physical health, so we still need to know what health is. This is likely to bring us back 
to the manifold issues of notions like normal functioning that we outlined for D6. There 
is no agreed-upon notion of normal functioning that we can simply call upon to fill out 
D10. 
A second problem is that D10 still seems to be too broad. Once again, TPN is 
a case in point. TPN is strictly regulated in healthcare contexts, because there are 
health-related harms associated with the improper administration of this nutrient 
solution. For instance, TPN carries a risk of blood infection. While there is a risk of a 
blood infection with any intravenous solution, the length of time that TPN is 
administered and the high glucose content of the solution makes infection risk a 
serious concern. In addition, if TPN is improperly formulated by incorrectly balancing 
the electrolytes in the solution, there is a substantial risk of arrhythmia and seizure. 
There is therefore just as much need to manage the potential health-related harms 




Our 10 definitions of drugs have not taken us any closer to a natural kind-based 
definition, functional kind-based definition, or even a social kind-based definition of 
drugs. Any combination of intrinsic, functional and social factors merely picks and 
chooses which elements of a basic list of properties to combine and emphasize, and 
each of those combinations runs into trouble. Although our discussion is by no means 
exhaustive, we do take it to cast doubt on the prospects for finding a robust definition 
of drugs that achieves the two desiderata identified in Section Two.  
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One way forward in our conceptual understanding of drugs is to give up or 
otherwise modify one of these two desiderata in an effort to save a conceptually 
monistic view of drugs. Recall the two desiderata: (i) everything considered to be a 
drug should be captured and (ii) everything that is not considered to be a drug should 
be ruled out. The focus of (ii), in particular, was on food and nutrients. A straightforward 
suggestion then is simply to give up on the contrast between medical drugs on the one 
hand, and food and nutrients on the other. While giving up the contrast with food will 
do little to resuscitate a functional or natural kind-definition of drugs, it does seem to 
bring two of the social kind-definitions back into play, specifically D8 and D10. So, for 
instance, we could adopt D8 and just concede that, within a medical context, food and 
nutrients are drugs because they have a therapeutic benefit. This is not so extreme 
an outcome, especially once we take into account the comparability in physical action 
between many drug molecules and nutrients, specifically for nutrient solutions like 
TPN. 
There are two important implications of adopting this response to the 
arguments presented here, however. First, if the administration of a drug is at least 
sufficient for medical treatment (as noted in Section Two), then the administration of 
food and nutrients in a hospital counts as a dimension of medical treatment and care 
as well. This would not be limited to TPN. Simply feeding a patient in order to ensure 
a positive health outcome would plausibly fall under the broad rubric of medical 
treatment. This would lift the ethical stakes when it comes to how food is managed 
inside a hospital. In addition, in so far as all drugs ought to be regulated in some way 
within a healthcare setting, it follows that food and nutrients should be subject to a 
similar regulatory framework. Similar implications carry forward to notions of health 
and normal functioning. If chronic drug-taking is sufficient to define ill-health and 
abnormal functioning, then patients on prescribed diets may well fall under these 
notions in so far as the food and nutrients prescribed satisfy the drug concept. This 
places an additional burden on conceptual analyses of health and disease. 
The second implication relates to placebos and excipients. If the drug concept 
is defined via D8 or, indeed, via any of the social kind-definitions provided in Section 
Six, then we have clear answers to the two demarcation questions identified in Section 
Two, namely: are placebos drugs? And are excipients drugs? The answer, in both 
cases, is ‘yes’. Both placebos and drugs can be administered with an aim of bringing 
about a therapeutic benefit (though, in the case of excipients, this may be an indirect 
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relationship based on the need for a delivery mechanism for a certain chemical). 
Similarly, placebos and excipients can have ill-effects and so there is reason to 
regulate them in the manner that drugs are regulated. If nothing else, this suggests a 
reconceptualization of placebo-controlled trials. Such trials should not be thought of 
as experiments in which drugs are compared with non-drugs. These are trials in which 
one drug is compared with another.  
A more positive corollary to these issues is whether ‘natural’ remedies are 
substances distinct from drugs. D8 suggests they are drugs when they are used with 
the aim of bringing about a therapeutic benefit. This reclassification would have the 
virtue of no longer exempting such substances from the risk-benefit analyses to which 
drugs are subjected. If natural products, such as specific herbal remedies, are exempt 
from such analyses, this can produce harm when adverse effects outweigh benefit 
(Seef et al. 2015). In other cases, evidence-based treatments are sometimes replaced 
with ‘natural’ products with no known benefit. A fairly common example is when 
chemotherapy or even cancer surgery is rejected in favour of herbal remedies, such 
as curcumin (an extract of turmeric), because of beliefs such natural substances are 
safer than drugs (see Nelson et al. 2017). If so-called natural remedies are deemed to 
be drugs and subjected to standard risk-benefit analysis and oversight, the potential 
problems of using them would be highlighted and, perhaps, avoided.  
For anyone wishing to avoid the implications of including food, placebos, 
excipients and other substances as drugs, conceptual monism about drugs will have 
to be abandoned and pluralism conceded. Has our discussion revealed a plurality of 
distinct medical drug concepts? There does seem to be a more or less natural 
cleavage between substances that fall under a particular functional kind—namely the 
kind specified by receptor theory and any associated pharmacological laws—and the 
rest, which share no particular physical or functional features in common. We can thus 
posit two distinct drug concepts instead of a single definition that captures all and only 
the substances considered to be drugs. 
 However, this ‘receptors and the rest’ pluralism faces an important question: is 
there anything that these two distinct concepts share in common such that they are 
both concepts of drugs? What would that common ground be? One plausible answer 
is that both conceptualize drugs as chemicals that are used in a medical setting for a 
therapeutic benefit. Thus, both concepts have something like D8 as a necessary 
condition, though they differ in what else they build into the drug concept. The 
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receptor-based concept of drugs adds to D8 the specification of a particular functional 
kind. The second, looser concept, by contrast adds nothing. By being non-specific 
about causal action, it manages to capture the miscellany of other substances 
considered to be drugs. If this basic picture is right, however, then yet again it will be 
difficult to keep food, placebos and excipients out of the second, non-receptor-based 
drug concept. For it seems that the necessary condition specified by D8 is also 
sufficient in this case.  
 Suppose, instead, that there is nothing that unifies the two drug concepts. It is 
unclear whether a form of pluralism this weak is deserving of the name. Rather, the 
situation looks more like a case of polysemy where, for historical reasons, people have 
come to use the term ‘drug’ to pick out two quite different things within a medical 
context, with no unifying rationale. Still, pluralism of this kind is possibly the only way 
to avoid the implications discussed above. If we are forced toward this form of 
pluralism about drugs, however, then we may need to reconsider whether we should 
continue talking univocally about drugs in medicine. What we really have is a range of 
different substances and a single term for them, without any unifying criterion for the 
use of that term. In that case, it might be better for our conceptual economy to dispense 
with drug talk and speak directly in terms of the various substances to which the term 
‘drug’ is applied. This would still provide a kind of answer to our two demarcation 
questions concerning placebos and excipients, by showing that those questions are 
not conceptually viable in the first place. 
  Ultimately, our goal is not to select between the different options that result 
from our investigation. It is striking, though, that two of the options we present 
challenge the distinction between drugs and food/nutrients. We are reluctant to 
recommend collapsing this distinction, however, because any conceptual 
understanding of drugs is in its infancy, and—as we noted at the outset—outcomes 
unacceptable to pharmacologists, clinicians and medical professionals will need a lot 
more justification. Furthermore, there may still be a way to rescue a monistic view of 
drugs despite our failure to find a viable candidate. Or, it could be that there is actually 
a way to develop a pluralistic account of drugs that manages to cleave them from food 
and other substances. We thus offer these options in the spirit of starting a broader 
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